Talazoparib plus enzalutamide shows no clear added benefit without DNA repair mutations

Adding the PARP inhibitor talazoparib to enzalutamide delayed disease progression in men with high-volume metastatic hormone-naïve prostate cancer, but the trial did not show a clear benefit over enzalutamide alone in patients whose tumours lacked actionable mutations. The combination also carried greater toxicity.…